- Conditions
- Ureter Injury
- Interventions
- Saline Injection 0.9%, Indigotindisulfonate sodium 0.8%
- Other · Drug
- Lead sponsor
- Prove pharm
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Albany, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 496
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Osteoarthritis
- Interventions
- Ropivacaine, Normal saline, Methylprednisolone
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Virus, Zika, Zika Virus Disease, Flavivirus Infections, Healthy Participants
- Interventions
- Placebo, PIZV
- Drug · Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 271 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 7
- States / cities
- Coral Gables, Florida • Miami, Florida • Lenexa, Kansas + 3 more
- Conditions
- Pulmonary Emphysema in Alpha-1 PI Deficiency
- Interventions
- Alpha-1 MP, 0.9% Sodium Chloride for Injection, USP
- Biological · Other
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Gainesville, Florida • Leesburg, Florida + 7 more
- Conditions
- Respiratory Failure, Hypotension and Shock, Hypotension on Induction, Intubation Complication, Anesthesia Intubation Complication
- Interventions
- Norepinephrine, Lactated Ringers, Intravenous, normal saline, Plasma-lyte
- Drug
- Lead sponsor
- Wright State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Dayton, Ohio
- Conditions
- Femoroacetabular Impingement
- Interventions
- regional anesthesia bupivacaine, regional anesthesia placebo
- Drug
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years to 45 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Cardiac Repolarization in Healthy Subjects
- Interventions
- ZTI-01, Moxifloxacin 400mg, Placebo IV
- Drug · Other
- Lead sponsor
- Nabriva Therapeutics AG
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Urinary Incontinence, Stress
- Interventions
- liposomal bupivacaine, Placebo
- Drug
- Lead sponsor
- TriHealth Inc.
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Acute Intermittent Porphyria
- Interventions
- givosiran (ALN-AS1), Sterile Normal Saline (0.9% NaCl)
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • San Francisco, California • New York, New York + 1 more
- Conditions
- Plantar Fasciitis
- Interventions
- Injection of 1.0 cc of 0.9% Saline, Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension, Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension, Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension
- Procedure
- Lead sponsor
- MiMedx Group, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Roanoke, Virginia
- Conditions
- Elevated Lipoprotein(a), Cardiovascular Disease
- Interventions
- ISIS 681257, Placebo
- Drug
- Lead sponsor
- Akcea Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 22
- States / cities
- Cottonwood, Arizona • Huntington Beach, California • La Jolla, California + 18 more
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1273, Placebo, mRNA-1273.222
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 4,328 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 48
- States / cities
- Banning, California • La Mesa, California • Lake Worth, Florida + 41 more
- Conditions
- Pain on IV Injection of Propofol.
- Interventions
- Lidocaine/tetracaine transdermal patch, Saline, Lidocaine
- Device · Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- belantamab mafodotin, Pembrolizumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Indianapolis, Indiana • Charlotte, North Carolina + 1 more
- Conditions
- Peripheral Neuropathy Due to Chemotherapy
- Interventions
- IncobotulinumtoxinA (Xeomin®, Merz) (INA), Normal saline
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Hemorrhage, Surgical, Tonsillar Bleeding
- Interventions
- Tranexamic Acid Injectable Product, Normal Saline
- Drug · Other
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Clostridoides Difficile Associated Disease
- Interventions
- C.difficile vaccine, Saline Placebo
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 32,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 141
- States / cities
- Athens, Alabama • Guntersville, Alabama • Huntsville, Alabama + 89 more
- Conditions
- Spasticity
- Interventions
- intramuscular Botox versus oral baclofen
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Epstein-Barr Virus Infection
- Interventions
- mRNA-1195.1, mRNA-1195.2, mRNA-1189, Placebo, mRNA-1195
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 482 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 34
- States / cities
- Anniston, Alabama • Tucson, Arizona • Huntington Beach, California + 30 more
- Conditions
- Solid Tumor Refractory to Standard Therapy
- Interventions
- SQ001 125mL/day, SQ001 250mL/day, SQ001 500mL/day, SQ001 625mL/day, Saline 0.9%
- Drug
- Lead sponsor
- Livzon Pharmaceutical Group Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
- Biological · Drug · Procedure
- Lead sponsor
- Northside Hospital, Inc.
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Healthy
- Interventions
- HF1K16, Placebo
- Drug
- Lead sponsor
- HighField Biopharmaceuticals Corporation
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Secaucus, New Jersey
- Conditions
- Critical Illness, Depressive Symptoms
- Interventions
- Ketamine (0.5 mg/kg), Normal Saline (0.9% NaCl)
- Drug · Other
- Lead sponsor
- Hospital Italiano de Buenos Aires
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Cytomegalovirus Infection
- Interventions
- mRNA-1647, Placebo
- Biological · Other
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 315 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 9
- States / cities
- Sacramento, California • Peoria, Illinois • Lenexa, Kansas + 5 more